Bulk maribavir 200MG tabs
Ended Awarded Last action
- Contract number
- 36C26025F0145
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $112,528
Award facts
- Contract value 100% obligated
- $112,528.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$16 | |
| Original award | $112,545 |
About this award
Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, was awarded a delivery order valued at $112,528.26 on February 5, 2025, for the supply of bulk Maribavir 200mg tablets, with a price adjustment reflecting two bottles. The contract is a firm fixed-price delivery order under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries no set-aside designation. The award is being funded by Veterans Integrated Service Network 20, a component of the Department of Veterans Affairs, with performance scheduled for completion by August 31, 2025, and fulfillment originating from Dublin, Ohio.
This delivery order falls under Takeda's broader strategic relationship with the VA, which includes a substantial Blanket Purchase Agreement valued at $131.0 million running from July 2025 through July 2026. Maribavir is an antiviral medication used in specialized treatment protocols, and this procurement demonstrates the VA's continued reliance on Takeda's specialized pharmaceutical products to support veteran healthcare needs. As with Takeda's other federal pharmaceutical contracts, this award reflects the streamlined procurement mechanisms available for critical medical products serving federal healthcare systems, where the specialized and limited-source nature of such medications typically precludes the use of set-aside programs.
Quick answers
Who was awarded contract 36C26025F0145?
36C26025F0145 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on February 5, 2025.
How much is contract 36C26025F0145 worth?
The government has obligated $112,528 on 36C26025F0145.
Is contract 36C26025F0145 an order under another contract?
Yes. 36C26025F0145 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0145 competed?
The extent of competition for 36C26025F0145 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award